Support for Vaccine Development
Deadline: 30 October 2015 5:00 p.m. CET
Anticipated Decision Date 30 November 2015
The High Impact project on Advanced Immunization Technologies (ADITEC), funded through the 7th Framework Programme of the European Union, aims to accelerate the development of novel and powerful immunization technologies for the next generation of human vaccines. ADITEC is coordinated by the Sclavo Vaccines Association (SVA): a non-profit organization that strives to ensure long-term sustainability of European vaccine R&D efforts.
ADITEC constitutes an important cornerstone of an expanded vaccine research partnership, geared to boost European research in the field of immunology and vaccinology. It is within this context that ADITEC will give interested vaccine R&D users free access to consortium “in house” available vaccinology expertise and technologies.
By facilitating better coordination among European organizations involved in vaccine research, ADITEC hopes to expand European industry capacity in terms of vaccine R&D and production, thus promoting competitiveness of European health industries and significantly impacting population health in the future.
Commissioned research for European Small and Medium size Enterprises (SME) and Public Health Organizations.
The ADITEC project is looking to support SMEs and public health organizations from within or outside the ADITEC consortium in vaccine development work that will result in public health benefit. We are actively seeking research proposals clearly aimed at vaccine development, where specific support can be requested in the areas listed below. These services are offered by current ADITEC consortium partners and are available free of charge to the requesting SME or public health organization, upon approval of the proposal. A total of 1,299,878 Euros from ADITEC funding was allocated and up to 100 k€ may requested per project. The ADITEC project will reimburse the service-providing ADITEC partners directly; no funds will be distributed to the SME or public health organization requesting and receiving the service. There will be no cost to the awarded SME or public health organization for the service provided. Resulting IP will be owned by the SME or public health organization receiving the service, and maybe shared with the ADITEC partner(s) performing the research. It will be expected that results of the “commissioned research work” will be made available to European users, and the ADITEC support will be acknowledged. Successful external applicants, if wished so, may apply to become an ADITEC “Affiliated Member” including all respective rights as described in the Affiliated Member Application.